Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jan 17:47:72-79.
doi: 10.1016/j.jdcr.2023.11.027. eCollection 2024 May.

Erosive pustular dermatosis-like eruption of the scalp secondary to amivantamab: A case series

Mariya N George  1 , Riyad N H Seervai  2   3 , Susan Y Chon  1   4
Affiliations
Case Reports

Erosive pustular dermatosis-like eruption of the scalp secondary to amivantamab: A case series

Mariya N George et al. JAAD Case Rep. .
No abstract available

Keywords: EGFR inhibitors; alopecia; amivantamab; erosive pustular dermatosis; immunotherapy; non–small cell lung cancer; oncodermatology.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
Case 1. A, Initial clinical presentation of acneiform rash. B, Improved acneiform rash 4 months into antibiotic treatment.
Fig 2
Fig 2
Case 1. A, Erosive pustular dermatosis-like eruption. A, Initial clinical presentation with crusted hemorrhagic erosions and pustules with alopecia on month 4 of treatment with amivantamab. B, Worsening symptoms with thick, yellow-brown crusts of erosions with alopecia on month 5. C, Improving symptoms after 3 week amivantamab holiday with decreased inflammation. D, Healed eruption with regrowth of hair 6 weeks after discontinuation of amivantamab.
Fig 3
Fig 3
Case 1. Friable 2-cm nodule on the left side of the frontal aspect of the scalp present 1 month after discontinuation of amivantamab.
Fig 4
Fig 4
Case 2. A, Erosive pustular dermatosis-like eruption at month 5 of amivantamab therapy with crusted erosions and nonscarring alopecia. B, Worsening symptoms at month 7 with thick, yellow-brown crusts of erosions with alopecia. C, Improving symptoms with regrowth of hair 6 weeks after cessation of amivantamab. D, Healed eruption with regrowth of hair 2.5 months after discontinuation of amivantamab.
Fig 5
Fig 5
Case 2. A, Initial presentation of paronychia of several toes and pyogenic granulomas on bilateral first toes at month 6 of therapy with amivantamab. B, C, Continued paronychia and resolution of pyogenic granulomas 1 month after discontinuation of amivantamab.
Fig 6
Fig 6
Case 3. A, Initial presentation of ulcerated, granulation lesions on the scrotum at month 9 of amivantamab therapy. B, Improved scrotal lesions after 1 month of drug holiday.
Fig 7
Fig 7
Case 3. Erosive pustular dermatosis-like eruption. A, On month 16 of amivantamab therapy with crusted hemorrhagic erosions on the frontal scalp with areas of alopecia. B, C, Healed eruption with regrowth of hair on month 20 of amivantamab.
Fig 8
Fig 8
Timeline in months since initiation of amivantamab. A, Case 1. B, Case 2. C, Case 3.
See this image and copyright information in PMC

References

    1. Park K., Haura E.B., Leighl N.B., et al. Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS Phase I study. J Clin Oncol. 2021;39(30):3391–3402. doi: 10.1200/JCO.21.00662. - DOI - PMC - PubMed
    1. Starace M., Iorizzo M., Trüeb R.M., et al. Erosive pustular dermatosis of the scalp: a multicentre study. J Eur Acad Dermatol Venereol. 2020;34(6):1348–1354. doi: 10.1111/jdv.16211. - DOI - PubMed
    1. Karanfilian K.M., Wassef C. Erosive pustular dermatosis of the scalp: causes and treatments. Int J Dermatol. 2021;60(1):25–32. doi: 10.1111/ijd.14955. - DOI - PubMed
    1. Seervai R.N.H., Cho W.C., Chu E.Y., et al. Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy. J Cutan Pathol. 2022;49(1):61–81. doi: 10.1111/cup.14145. - DOI - PubMed
    1. Hu J.C., Sadeghi P., Pinter-Brown L.C., Yashar S., Chiu M.W. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56(2):317–326. doi: 10.1016/j.jaad.2006.09.005. - DOI - PubMed

Publication types